Novo Nordisk said Wednesday that the Ministry of Health and Welfare would expand insurance benefits for its Norditropin Nordiflex, a growth hormone injection, from Feb. 13.
With the expanded reimbursement, patients with pediatric and adult growth hormone deficiency, Turner syndrome, and chronic kidney failure will receive insurance benefits. In the case of Turner's syndrome, if patients do not respond well to the current maximum treatment dosage of 1.0 IU/kg per week, they will be able to receive up to 1.4 IU/kg per week.
The company has also lowered the drug price from 172,929 won ($155) to 166,012 won. With the drop in drug prices, the company will lessen the financial burden for patients with idiopathic short stature, who are not covered by insurance.
“As Nordifropin Nordiflex has proven its efficacy and safety through various clinical trials as well as economic benefits through an expansion of insurance, the company expects it will help patients with a growth disorder," Novo Nordisk Korea CEO Rana Azfar Zafar said.